Toxic epidermal necrolysis (TEN) Lyell's syndrome

References

• Lyell A. Toxic epidermal necrolysis: an eruption resembling scalding of the skin. Br J Dermatol 1956; 68: 355–61
   PubMed Web of Science ®Google Scholar
• Lyell A. A review of toxic epidermal necrolysis in Britain. Br J Dermatol 1967; 79: 662–71
   PubMed Web of Science ®Google Scholar
• Lyell A. Toxic epidermal necrolysis (the scalded skin syndrome). Br J Dermatol 1979; 100: 69–86
   PubMed Web of Science ®Google Scholar
• Dowd P. M., Champion R. H. Toxic epidermal necrolysis. Text book of dermatology, Vol 2, 6th edn, R. H Champion, J. L Burton, D. A Burns. Blackwell Science, London 1998; 2085–7, In
   Google Scholar
• Fritsch P. O., Ruiz‐Maldonado R. Erythema multiforme, Stevens Johnson syndrome and toxic epidermal necrolysis.. 543–557, In Dermatology in General Medicine. Eds. Erwin M, Fredberg G, Arthor Z, Klaus W, Frank A, Goldsmith LA, Stephen KA, Fitzpatrick IM, 6th Ed. MC Graw Hill, NewYork, 2003, pp
   Google Scholar
• Ohlenschlaege K. Toxic epidermal necrolysis and Stevens Johnson syndrome. Acta Derm Venereol 1966; 46: 204–9
   Google Scholar
• Sehgal V. N., Bahadur P., Ghosh S. K. Toxic epidermal necrolysis as a result of anti‐tubercular drugs. Indian J Chest Dis 1973; 15: 57–60
   Google Scholar
• Rist T. E., Abele D. C. Current concept of toxic epidermal necrolysis. South Med J 1975; 68: 22–6
   Google Scholar
• Ranglione M. C., Pablos‐Mendaz A., Battan R. Clinical features and management of severe dermatological reactions to drugs. Drugs Saf 1990; 5: 39–64
   Google Scholar
• Lyell. A requiem for toxic epidermal necrolysis. Br J Dermatol 1990; 122: 837–40
   Google Scholar
• Chan H. L. Observation on drug induced toxic epidermal necrolysis in singapore. J Am Acad Dermatol 1984; 10: 973–8
   PubMedGoogle Scholar
• Adzick N. S., Kum S. H., Bandoc C. C., Quinby W. C., Remensnyder J. P. Management of toxic epidermal necrolysis in a pediatric burn centre. Am J Dis Child 1985; 139: 499–502
   PubMedGoogle Scholar
• Revuz J., Penso O., Roujeau J. C., Guillaume J. C., Payne C. R., Wechsler J., et al. Toxic epidermal necrolysis – clinical findings and prognosis factors in 87 patients. Arch Dermatol 1987; 123: 1160–5
   PubMed Web of Science ®Google Scholar
• Bastuji‐Garin S., Rzany B., Stern R. S., Shear N. H., Naldi L., Roujeau J. C. Clinical classification of cases of toxic epidermal necrolysis, Stevens Johnson syndrome and EM. Arch Dermatol 1993; 129: 92–6
   PubMed Web of Science ®Google Scholar
• Roujeau J. C. The spectrum of Stevens Johnson syndrome and toxic epidermal necrolysis – a clinical clarification. J Invest Dermatol 1994; 102: 285–305
   Google Scholar
• Roujeau J. C. Stevens Johnson syndrome and toxic epidermal necrolysis are severity variants of the same disease, which differ from erythema multiformae. J Dermatol 1997; 4: 726–9
   Google Scholar
• Moeckenhaup F. M., Schopf E. Epidemiology of drug induced severe skin reactions. Semin Cutan Med Surgery 1996; 15: 236–43
   Google Scholar
• Revuz J. E., Roujeau J. C. Advances in toxic epidermal necrolysis. Semin Cutan Med Surg 1996; 15: 258–66
   PubMedGoogle Scholar
• Schwartz R. A. Toxic epidermal necrolysis. Cutis 1997; 59: 23–8
   Google Scholar
• Nigen S., Knowles S. R., Shear N. H. Drug eruptions: approaching the diagnosis of drug induced skin diseases. J Drugs Dermatol 2003; 2: 278–99
   PubMedGoogle Scholar
• Bachot N., Ranjean J. C. Differential diagnosis of severe cutaneous drug eruptions. Am J Clinical Dermatol 2003; 4: 501–72
   Google Scholar
• Schopf E., Stuhmer A., Rzany B., Victor N., Zentgraf R., Kapp J. F. Toxic epidermal necrolysis and Stevens Johnson syndrome: an epidemiological study from West Germany. Arch Dermatol 1991; 127: 839–42
   PubMedGoogle Scholar
• Rzany B., Mockenhaupt M., Baur S., Schroder W., Stocker U., Mueller J., Hollander N., Bruppacher R., Schopf E., et al. Epidemiology of erythema exsudativum multiforme majus, Stevens‐Johnson syndrome and toxic epidermal necrolysis in Germany (1990–92): structure and result of a population‐based registry. J Clin Epidemiol 1996; 49: 769–73
   PubMed Web of Science ®Google Scholar
• Roujeau J. C. Toxic epidermal necrolysis: incidence and drug etiology in France 1981–1985. Arch Dermatol 1990; 126: 37–42
   PubMed Web of Science ®Google Scholar
• Chan H. L., Sten R. S., Arndt K. A., et al. The incidence of EM, Stevens Johnson syndrome and toxic epidermal necrolysis – a population based study. Arch Dermatol 1990; 126: 1103–4
   Google Scholar
• Rzany B., Mockenhaupt M., Stocker U., Hamouda O., Schopf E. Incidence of Stevens Johnson syndrome and toxic epidermal necrolysis in patient with AIDS in Germany. Arch Dermatol 1993; 129: 1059–63
   PubMedGoogle Scholar
• Kelly J. P., Auquier A., Rzany B. An international collaborative case control study of reverse cutaneous adverse reactions (SCAR). Design and methods. J Clin Epidemiol 1995; 48: 1099–108
   PubMed Web of Science ®Google Scholar
• Foman R., Koren G., Shear N. H. EM, Stevens Johnson syndrome and toxic epidermal necrolysis in children: a review of 10 years experience. Drug Saf 2002; 25: 965–72
   Google Scholar
• Metry D. W., Jung P., Levy M. L. Use of intravenous immunoglobulin in children in Stevens Johnson syndrome and toxic epidermal necrolysis. Pediatrics 2003; 112: 1430–6
   PubMed Web of Science ®Google Scholar
• Inamo Y., Okubo T., Wada M., Fuchigami S., Hashimoto K., Fuchigami T., et al. Intravenous ulinastatin therapy for Stevens Johnson syndrome and toxic epidermal necrolysis in pediatric patients. Int Arch Allergy Immunol 2002; 127: 89–94
   PubMed Web of Science ®Google Scholar
• Shun H. T., Chang M. W. Drug eruptions in children. Curr Probl Pediatr 2001; 31: 207–34
   Google Scholar
• Rangleon M., Lande T. A. Toxic epidermal necrolysis in children: an update. Clin Pediatr 2000; 39: 687–94
   Google Scholar
• Swell M. L. Pediatric burns – management of thermal, electrical, chemical and burn‐like dermatologic conditions. Pediatr Ann 2000; 29: 367–78
   Google Scholar
• Sharma V. K., Dhar S. Clinical pattern of cutaneous drug erythema in children and adolescents of north India. Pediatr Dermatol 1995; 12: 178–83
   PubMed Web of Science ®Google Scholar
• Prendiville J. S., Herbert A. A., Greenwald M. J., Esterly M. B. Management of Stevens Johnson syndrome and toxic epidermal necrolysis in children. J Pediatr 1989; 115: 881–7
   PubMed Web of Science ®Google Scholar
• Hernbugh A. Stevens Johnson syndrome after mass prophylaxis with sulfadoxine for cholera in Mozambique. Lancet 1985; 1: 1072–5
   Google Scholar
• Auquier Dumant A., Mockenhaupt M., Naldi L., Correia O., Schroder W., Roujeau J. C., et al. Correlation between clinical patterns and causes of EM majus, Stevens‐Johnson syndrome and toxic epidermal necrolysis – results of an international prospective study. Arch Dermatol 2002; 138: 1019–24
   Google Scholar
• Leenutaphong V. Stevens Johnson syndrome and toxic epidermal necrolysis in Thailand. Int J Dermatol 1993; 32: 428–31
   Google Scholar
• Kaufman D. W. Epidemologic approaches to the study of toxic epidermal necrolysis. J Invest Dermatol 1994; 102: 315–35
   Google Scholar
• Mandes S. M. Serious and life threatening drug eruption. Am Fam Physician 1995; 51: 1865–72
   Google Scholar
• Yeung C. K., Ma S. Y., Hon C., Peiris M., Chan H. H. Etiology in 16 cases of toxic epidermal necrolysis and Stevens Johnson syndrome admitted within eight months in a teaching hospital. Acta Derm Venereol 2003; 83: 179–82
   Google Scholar
• See S., Mumford J. M. Trimethoprim/sulphamethoxazole induced toxic epidermal necrolysis. Ann Pharmacother 2001; 35: 694–7
   Google Scholar
• Fritsch P. O., Sidoroff A. Drug induced Stevens Johnson syndrome/toxic epidermal necrolysis. Ann J Clin Dermatol 2000; 1: 349–60
   PubMedGoogle Scholar
• Revuz J. New advances in severe adverse drug reactions. Dermatol Clin 2001; 19: 677–709
   Google Scholar
• Thong B. y., Leong K. P., Tang C. Y., Chng H. H. Drug allergy in a general hospital. Ann Allergy Asthma Immunol 2003; 90: 342–7
   PubMed Web of Science ®Google Scholar
• Schenfield N. Phenytoin in cutaneous medicine. Dermatol Online J 2003; 9: 6
   Google Scholar
• Sogut A., Yilmaz A., Kilinc M. Suspected lamotrigine induced toxic epidermal necrolysis. Acta Neurol Belg 2003; 103: 95–8
   Google Scholar
• Schillieng R. G., Shapiro L. E., Shear N. H. Lamotrigine induced severe cutaneous adverse reactions. Epilepsia 1998; 39: S22–S26
   Google Scholar
• Dher S., Tooh S. K. Are carbamazapine induced Stevens Johnson syndrome and toxic epidermal necrolysis common in non‐epeleptics patients. Dermatology 1999; 199: 194
   Google Scholar
• Warnodk J. K., Morris D. W. Adverse cutaneous reactions to mood stabilizers. Am J Clin Dermatol 2003; 4: 21–30
   Google Scholar
• Baba M., Karaka M., Sungar. A. K. The anticonvulsant hypersensitivity syndrome. J Eur Acad Dermatol Venereol 2003; 17: 399–401
   Google Scholar
• Bigby M., Sten R. Cutaneous reaction to non‐steroidal anti‐inflammatory drugs – a review. J Am Acad Dermatol 1985; 12: 866–76
   PubMed Web of Science ®Google Scholar
• Mockenhaupt M., Kelly J. P., Kaufmann D., Stern R. S., SCAR Study Group. The risk of Stevens Johnson syndrome and toxic epidermal necrolysis associated with anti‐inflammatory drugs. A multination perspective. J Rheumatol 2003; 30: 2234–40
   PubMed Web of Science ®Google Scholar
• Smill H. R., Soft A. M., Block M. M. Dermatological adverse effects with anti‐malarial drug mefloquine. Clin Dermatol 1999; 24: 249–54
   Google Scholar
• Andersin J. A. Antibiotic drug allergy in children. Curr Opin Pediatr 1994; 6: 656–60
   Google Scholar
• Livasy C. A., Kaplan A. M. Ciprofloxacin induced toxic epidermal necrolysis. Dermatology 1997; 195: 173–5
   Google Scholar
• Laleattahan I., Ozyar E., Sahan S. Two cases of Stevens Johnson syndrome/toxic epidermal necrolysis possibly induced by ami‐fostine during radiotherapy. Br J Dermatol 2000; 143: 1072–3
   Google Scholar
• Bhattacharya S. K., Singh N. K., Prasad R. C., Sinha P. R. Some unusual and severe forms of adverse drug reactions: a call for setting up adverse drug reaction monitoring centres. J Assoc Physicians India 1998; 46: 675–7
   Google Scholar
• Bayard P. J., Berger T. G., Jacobson M. A. Drug hypersensitivity reactions and HIV disease. J Acquir Immune Defic Syndr 1992; 5: 1237–57
   PubMed Web of Science ®Google Scholar
• Fagot J. P., Mockenhaupt M., Bouwes, Bavinck J. N., Naldi L., Viboud C., Roujeau J. C., et al. Nevirapine and the risk of Stevens Johnson syndrome and toxic epidermal necrolysis. Acquir Immune Defic Syndr 2001; 28: 1843–8
   Google Scholar
• Rotunda A., Hirsch R. J., Scheinfeld N., Weinberg J. M. Severe cutaneous reactions associated with the use of HIV medication. Acta Derm Venereol 2003; 83: 1–9
   PubMed Web of Science ®Google Scholar
• Shoss R. G., Rayhanzadeh S. Toxic epidermal necrolysis following measles vaccination. Arch Dermatol 1974; 110: 766–70
   Google Scholar
• Garnier G. Lyell's syndrome. Presse Med 1962; 70: 1437–40
   Google Scholar
• Feck G. L., Herzig G. P., Elias P. M. Toxic epidermal necrolysis in a patient with graft versus host disease. Arch Dermatol 1972; 105: 561–9
   Google Scholar
• House R. A., Jakubovic H., Wong L. Work related toxic epidermal necrolysis. J Occup Dis 1992; 34: 135–9
   Google Scholar
• Radimer J. F., Davis J. I. Fumigant induced toxic epidermal necrolysis. Arch Dermatol 1974; 110: 103–4
   Google Scholar
• Pegram PS J. r., Mountz J. D., Bar R. R. Ethambutol induced toxic epidermal necrolysis. Arch Intern Med 1981; 141: 1677–8
   Google Scholar
• Roujeau J. C., Kelly J. P., Naldi L., Rzany P., Stern R. S., Anderson T., et al. Medication use and the risk of Stevens Johnson syndrome and toxic epidermal necrolysis. N Engl J Med 1995; 333: 1600–7
   PubMed Web of Science ®Google Scholar
• Aubock J. Asymptomatic hyperuricemia and allopurinol induced toxic epidermal necrolysis. Br Med J 1985; 290: 1969–71
   Google Scholar
• Witkowski J. A., Parish L. C. Cutaneous reaction to antibacterial agents. Skinmed 2002; 1: 33–4
   Google Scholar
• Malde S. L. Ofloxacin a probable cause of toxic epidermal necrolysis. Ann Pharmacother 2001; 35: 388–90
   Google Scholar
• Digwood‐Lettieris S., Reilly K. J., Haith LR J. r., Patton M. L., Guilday R. J., Cawley M. J., Ackermann B. H., et al. Levofloxacin induced toxic epidermal necrolysis. Pharmacotherapy 2002; 26: 789–93
   Google Scholar
• Leone R., Venegoni M., Motola D., Moretti U., Piazzetti V., Cocci A., et al. Adverse reactions related to the use of fluoroquinolones. Drug Saf 2003; 26: 109–20
   PubMed Web of Science ®Google Scholar
• Hallgren J., Tengvall‐Linder M., Persson M., Wahlgren C. F., et al. Stevens Johnson syndrome associated with ciprofloxacin. J Am Acad Dermatol 2003; 49: S264–S269
   Google Scholar
• Demiral A. N., Yerehankan O., Simsir V., Alpsoy E. Amifostine induced toxic epidermal necrolysis. Jpn J Clin Oncol 2002; 32: 477–9
   PubMed Web of Science ®Google Scholar
• Rocha J. L., Kondo W., Baptista M. J., Da Cunha C. A., Martins L. T. Uncommon vancomycin‐induced side effects. Braz J Infect Dis 2002; 6: 196–200
   PubMedGoogle Scholar
• Roujeau J. C., Huynh T. N., Bracq C., Guillaume J. C., Revuz J., Touraine R. Genetic susceptibility to toxic epidermal necrolysis. Arch Dermatol 1987; 123: 1171–3
   PubMed Web of Science ®Google Scholar
• Stevens D., Swift P. G., Johnstone P. G., Kearney P. J., Corner P. D., Burman D. Mycoplasma pneumoniae infections in children. Arch Dis Child 1978; 53: 38–42
   PubMed Web of Science ®Google Scholar
• Ball R., Ball L. N., Wise R. P., Braun M. M., Beeler J. A., Salive M. E. Stevens Johnson syndrome and toxic epidermal necrolysis after vaccination. Pediatr Infect Dis J 2001; 20: 219–23
   PubMed Web of Science ®Google Scholar
• Paul C., Wolkenstein P., Adle H., Wechsler J., Garchon H. J., Revuz J., et al. Apoptosis as a mechanism of health in toxic epidermal necrolysis. Br J Dermatol 1996; 134: 710–14
   PubMed Web of Science ®Google Scholar
• Mauri–Hellweg D., Bettens F., Mauri D., Brander C., Hunziker T., Pichler W. J. Activation of drug‐specific CD4+ and CD8+ T cells in individuals allergic to sulfonamides, phenytoin and carbamazepine. J Immunol 1995; 155: 462–8
   PubMed Web of Science ®Google Scholar
• Correia O. Cutaneous T‐cell recruitment in toxic epidermal necrolysis. Further evidence of CD‐8 lymphocyte involvement. Arch Dermatol 1993; 129: 466–70
   PubMedGoogle Scholar
• Paquet P. Immunoregulatory effector cells on drug induced toxic epidermal necrolysis. Am J Dermatopathol 2000; 22: 413–18
   Google Scholar
• Breathnach S. M. Mechanism of drug eruption – Part I. Australas J Dermatol 1995; 36: 121–7
   Google Scholar
• Shear N. H. Differences in metabolism of sulfonamides predisposing to idiosyncratic toxicity. Ann Intern Med 1986; 105: 179–84
   PubMed Web of Science ®Google Scholar
• Czelez D., Chodorowska G., Lecewiz‐Torun B. Plasma activity of interleukin 6 and some active phase proteins in severe drug induced skin adverse reaction. Ann Univ Marie Curie Sklodwska [Med] 2002; 57: 62–7
   Google Scholar
• Lerner L. H., Qureshi A. A., Reddy B. V., Lerner E. A. Nitric oxide synthase in toxic epidermal necrolysis and Stevens‐Johnson syndrome. J Invest Dermatol 2000; 114: 196–9
   PubMed Web of Science ®Google Scholar
• Posadas S. J., Torres M. J., Mayorga C., Juarez C., Blanca M. Gene expression levels of cytokine profile and cytotoxic markers in non‐immediate reaction to drugs. Blood Cell Mol Dis 2002; 29: 179–89
   PubMed Web of Science ®Google Scholar
• Abe R., Shimzu T., Shibaki A., Nakamura H., Watanabe H., Shimizu H. Toxic epidermal necrolysis and Stevens Johnson syndrome are induced by soluble Fas Ligand. Am J Pathol 2003; 162: 1515–20
   PubMed Web of Science ®Google Scholar
• Roujeau J. C. Drug induced toxic epidermal necrolysis II: Current aspects. Clin Dermatol 1993; 11: 493–8
   Google Scholar
• Conger L. A. Dilantin hypersensitivity reaction. Cutis 1996; 57: 223–6
   Google Scholar
• Wolken Stein P., Carrige V., Clarued D. A slow aceylator genotype is a risk factor for sulphonamide induced toxic epidermal necrolysis and Stevens Johnson syndrome. Pharmacogenetics 1995; 5: 255–8
   Google Scholar
• Dietrich A., Kawakubo Y., Rzany B., Mockenhaupt M., Simon J. C., Schopf E. Low N‐acetylating capacity in patient with Stevens‐Johnson syndrome and toxic epidermal necrolysis. Exp Dermatol 1995; 4: 313–16
   PubMedGoogle Scholar
• Brocville H., Murch P., Goydadin A. C. N‐acetyltransferase 2‐acetylation polymorphism. Skin Pharmacol Appl Skin Physiol 2003; 16: 386–92
   Google Scholar
• Wolkenstein P., Revuz J. Drug induced reverse skin reactions, management and prevention. Drug Saf 1995; 13: 56–68
   Google Scholar
• Wolkenstein P., Revuz J. Metabolic predisposition to cutaneous adverse drug reactions – role in toxic epidermal necrolysis caused by sulphonamide and anti‐convulsants. Arch Dermatol 1995; 131: 544–8
   PubMed Web of Science ®Google Scholar
• Chave T. A., Mortimer N. J., Sladden M. J., Hall A. P., Hutchinson P. E. Toxic epidermal necrolysis: current evidence, practical management and future directions. Br J Dermatol 2005; 153: 241–53
   PubMed Web of Science ®Google Scholar
• Revuz J., Roujeau J. C., Guillaume J. E., Penso D., Touraine R. Treatment of toxic epidermal necrolysis – Creteil's experience. Arch Dermatol 1987; 123: 1156–8
   Google Scholar
• Roujeau J. C., Revuz J. Intensive care in dermatology. Recent advances in dermatology, Vol 8, R. H Champion, R. J Pye. Churchill Livingstone, Edinburgh 1990; 85–99, In
   Google Scholar
• Rzany B., Herup O., Mockenhaupt M. Histopathological and epidemiological characteristics of patients with EM major, Stevens Johnson syndrome and toxic epidermal necrolysis. Br J Dermatol 1996; 135: 6–11
   PubMed Web of Science ®Google Scholar
• Knowles S., Shapiro L., Shear N. H. Serious dermatologic reactions in children. Curr Opin Pediatr 1997; 9: 388–95
   PubMed Web of Science ®Google Scholar
• Bachot N., Ronjeau J. C. Physiopathology and treatment of severe drug reactions. Curr Opin Allergy Clin Immunol 2001; 1: 293–8
   Google Scholar
• Lebargy F., Wolkenstein P., Glisselbrecht M., Lange F., Fleury‐Feith J., Delclaux C., et al. Pulmonary complications in toxic epidermal necrolysis – a prospective clinical study. Intensive Care Med 1997; 23: 1237–44
   PubMed Web of Science ®Google Scholar
• Grando S. A., Grando A. A., Glukhenky B. T., Doguzov V., Nguyen V. T., Holubar K. History and clinical significance of mechanical symptoms in blistering dermatoses: a reappraisal. J Am Acad Dermatol 2003; 48: 86–92
   PubMed Web of Science ®Google Scholar
• Wong K. C., Kennady P. J., Leus S. Clinical manifestation and outcome in 17 cases of Stevens Johnson syndrome and toxic epidermal necrolysis. Australas J Dermatol 1999; 40: 131–4
   PubMedGoogle Scholar
• Kamaliah M. D., Zainal D., Mokhtar M., Nazmi N. EM, Stevens Johnson syndrome and toxic epidermal necrolysis in North eastern Malaysia. Int J Dermatol 1998; 37: 520–3
   Google Scholar
• Lin T. K., Hsu M. M., Lee J. X. Clinical resemblance of widespread bullous FDE to Stevens Johnson syndrome and toxic epidermal necrolysis. J Formos Med Assoc 2002; 101: 572–6
   Google Scholar
• Prendiville J. Stevens Johnson syndrome and toxic epidermal necrolysis. Adv Dermatol 2002; 18: 151–7
   Google Scholar
• Mclvor R. A. Acute and chronic respiratory complications of toxic epidermal necrolysis. J Burn Care Rehabil 1996; 17: 237–42
   Google Scholar
• Michel P. Ileal involvement in toxic epidermal necrolysis. Dig Dis Sci 1993; 38: 1938–41
   Google Scholar
• Blum L. Renal involvement in toxic epidermal necrolysis. J Am Acad Dermatol 1996; 34: 1088–93
   Google Scholar
• Belfor R Jr. Ocular complication of Stevens Johnson syndrome and toxic epidermal necrolysis in patients with acquired immune deficiency syndrome. Cornea 1991; 10: 536–8
   Google Scholar
• Power W. J., Ghoranishi M., Merayo‐Lloves M. J., Neves R. A., Foster C. S. Analysis, the acute ophthalmologic manifestations of EM/Stevens Johnson syndrome/toxic epidermal necrolysis disease spectrum. Ophthalmology 1995; 102: 1669–76
   PubMed Web of Science ®Google Scholar
• Ayangco L., Roger H. S. 3rd oral manifestation of erythema multiformae. Dermatol Clin 2003; 21: 195–205
   Google Scholar
• Bastuji‐Garin S., Fouchard N., Bertocchi N., Roujeau J. C., Revus J., Wolkenstein P. SCORTEN: A severity‐of‐illness score for toxic epidermal necrolysis. J Invest Dermatol 2000; 115: 149–52
   PubMed Web of Science ®Google Scholar
• Avakian R. Toxic epidermal necrolysis. A review. J Am Acad Dermatol 1991; 25: 69–77
   PubMed Web of Science ®Google Scholar
• Sehgal V. N., Jain S., Bhattacharya S. N. Cutaneous drug reactions. J Eur Acad Derm Venereol 1993; 2: 281–95
   Google Scholar
• Broz L., Kripner J. Non thermal skin affections. Acta Chir Plast 2000; 42: 11
   Google Scholar
• Gower N. M. Management of toxic epidermal necrolysis. Hosp Med 2000; 61: 778–81
   Google Scholar
• Sane S. P., Bhat A. D. Stevens Johnson syndrome and toxic epidermal necrolysis challenges and recognition and management. J Assoc Physicians India 2000; 48: 999–1003
   Google Scholar
• Sharma V. K., Selluraman G., Kunner B. Cutaneous adverse drug reactions clinical pattern and causative agents. A 6 year series from India. J Post Grad Med 2001; 47: 95–9
   PubMedGoogle Scholar
• Ghislam P. O., Roujean J. C. Treatment of severe drug reactions and Stevens Johnson syndrome and toxic epidermal necrolysis hypersensitivity syndrome. Dermatol Online J 2002; 8: 5
   Google Scholar
• Demling R. H., Ellerbe S., Lowe N. J. Burn unit management of toxic epidermal necrolysis. Arch Surg 1978; 113: 758–9
   PubMedGoogle Scholar
• McGee T., Munster A. Toxic epidermal necrolysis: mortality reduced with early referral to a regional burn centre. Plast Reconstr Surg 1998; 102: 1018–22
   PubMed Web of Science ®Google Scholar
• Halebian P. H., Corder V. J., Madden M. R., Finklestein J. L., Shires G. T. Improved burn center survival of patients with toxic epidermal necrolysis managed without corticosteroids. Ann Surg 1986; 204: 503–12
   PubMed Web of Science ®Google Scholar
• Khoo A. K., Foo C. L. Toxic epidermal necrolysis in a burns centre – a 6 year review. Burns 1996; 22: 275–8
   Google Scholar
• Stern R. S. Improving the outcome of patients with toxic epidermal necrolysis and Stevens Johnson syndrome. Arch Dermatol 2000; 136: 410–11
   Google Scholar
• Ellis M. W., Oster C. N., Turiansky G. W., Blanchard J. R. A case report and a proposed algorithm for the transfer of patients with Stevens Johnson syndrome and toxic epidermal necrolysis to a burn centre. Mil Med 2002; 167: 701–4
   Google Scholar
• Garcia‐Doval I., LeCleach L., Bocquet H., Otero X. L., Roujeau J. C. Toxic epidermal necrolysis and Stevens Johnson syndrome. Does early withdrawal of drugs decrease the risk of death. Arch Dermatol 2000; 136: 323–7
   PubMed Web of Science ®Google Scholar
• Eisen E. R., Fush J., Shear N. H. Management of drug induced toxic epidermal necrolysis. J Cutan Med Surg 2000; 4: 96–102
   Google Scholar
• Wheeler CE J. r., Briggaman R. A., Puitz E. M. Corticosteroids in the treatment of skin disorders. Am Fam Physician 1973; 7: 130–40
   Google Scholar
• Breathnach S. M. Management of drug eruption Part II. Diagnosis and treatment. Australas J Dermatol 1995; 36: 187–9
   Google Scholar
• Wolkenstein P., Chosidow O., Flechet M. L., Robbiola O., Paul M., Dume L., et al. Patch testing in severe cutaneous adverse drug reactions including Stevens Johnson syndrome and toxic epidermal necrolysis. Contact Dermatitis 1996; 35: 234–6
   PubMed Web of Science ®Google Scholar
• Sanwo M., Nwadiuko R., Beall G. Use of intravenous immunoglobulin in the treatment in reverse cutaneous drug reactions in patient with acquired immunodeficiency syndrome. J Allergy Clin Immunol 1996; 98: 1112–15
   PubMedGoogle Scholar
• Bachot N., Boujeau J. C. Intravenous immunoglobulin in the treatment of reverse drug eruption. Curr Opin Allergy Clin Immunol 2003; 3: 269–74
   PubMed Web of Science ®Google Scholar
• Prains C., Vittorio C., Padilla R. S., Hunziker T., Itin P., Forster J., et al. Effect of high dose intravenous immunoglobulin therapy in Stevens‐Johnson syndrome. Dermatology 2003; 207: 96–9
   Google Scholar
• Bachot N., Revuz J., Roujeau J. C. Intravenous immunoglobulin treatment for Stevens‐ Johnson syndrome and toxic epidermal necrolysis: a prospective noncomparative study showing no benefit on mortality or progression. Arch Dermatol 2003; 139: 33–6
   PubMedGoogle Scholar
• Egan C. A. Plasmaphoresis as an adjunct treatment in toxic epidermal necrolysis. J Am Acad Dermatol 1999; 40: 458–62
   PubMed Web of Science ®Google Scholar
• Furabake A. Lack of significant treatment effect of plasma exchange in the treatment of drug induced toxic epidermal necrolysis. Intensive Care Med 1999; 25: 1307–10
   Google Scholar
• Sanclemente G., De la Roche C. A., Escobar C. F., Falabella R. Pentoxyfylline in toxic epidermal necrolysis and Stevens Johnson syndrome. Int J Dermatol 1999; 38: 878–9
   PubMed Web of Science ®Google Scholar
• Tan A. W., Thong B. Y., Yip L. W., Chng H. H., Ng S. K. High‐dose intravenous immunoglobulin in the treatment of toxic epidermal necrolysis: an Asian series. J Dermatol 2005; 32: 1–6
   PubMedGoogle Scholar
• Chen K. T., Twu S. J., Chang H. J. Outbreak of Stevens Johnson syndrome and toxic epidermal necrolysis associated with mebendazole and metronidazole. Am J Public Health 2003; 93: 489–92
   Google Scholar
• Fournier S. Toxic epidermal necrolysis associated with Mycoplasma pneumoniae infection. Eur J Clin Micobiol Infect Dis 1995; 14: 558–9
   Google Scholar
• Bradley T., Brown R. E., Kucan J. O., Smoot E. C 3rd., Hussmann J. Toxic epidermal necrolysis. A review and report of the successful use of Biobrane for early wound coverage. Ann Plast Surg 1995; 35: 124–32
   Google Scholar
• Lerhrer‐Bell K. A., Kirsner R. S., Tallman P. G., Kerdel F. A. Treatment of the cutaneous involvement in Stevens Johnson syndrome and toxic epidermal necrolysis with impregnated dressings. Arch Dermatol 1998; 134: 877–9
   Google Scholar
• Roujeau J. C. Treatment of severe drug eruption. J Dermatol 1999; 26: 718–22
   PubMedGoogle Scholar
• Haber J., Hopman W., Gomez M., Cartotto R. Late outcomes in adult survivors of toxic epidermal necrolysis after treatment in a burn centre. J Burn Care Rehabil 2005; 26: 33–41
   Google Scholar